JointHealth™ express August 10, 2019
Correction to JointHealth™ express
Correction to the JointHealth™ express of August 9, 2019 listing for baricitinib (Olumiant®) and etanercept (Erelzi®) in Quebec
Our August 9, 2019 JointHealth™ express incorrectly reported that baricitinib (Olumiant®) for the treatment of rheumatoid arthritis (RA) and etanercept (Erelzi®) for the treatment of psoriatic arthritis (PsA) were listed on the Quebec drug formulary (la RAMQ). While they have received a positive recommendation to list from the Institut national d'excellence en santé et services sociaux (INESSS), they are not yet listed on the province’s formulary.
Correction to JointHealth™ express
Correction to the JointHealth™ express of August 9, 2019 listing for baricitinib (Olumiant®) and etanercept (Erelzi®) in Quebec
Our August 9, 2019 JointHealth™ express incorrectly reported that baricitinib (Olumiant®) for the treatment of rheumatoid arthritis (RA) and etanercept (Erelzi®) for the treatment of psoriatic arthritis (PsA) were listed on the Quebec drug formulary (la RAMQ). While they have received a positive recommendation to list from the Institut national d'excellence en santé et services sociaux (INESSS), they are not yet listed on the province’s formulary.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.